当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Takahiro Nakashima, KeijiMatsuda, Shin-yaHirahara and Tetsuya Tono
We performed BonebridgeTM (BB) implantation as a clinical trial. Transcutaneous bone conduction implants (BCIs) have not been approved for medical use in Japan, and the use of BB has been reported in few cases in Asia. The BB was used for a 16-year-old male who complained of bilateral mixed hearing loss due to bilateral congenital external auditory meatus atresia and microtia. Although he had already undergone percutaneous BAHA surgery, skin disorders inhibited the continued use of a sound processor. The BB was implanted at the opposite side without any intra- or postoperative complications. Transcutaneous BCI provides advantages over percutaneous BCI with respect to postoperative skin care and cosmetic outcomes for patients who experienced difficulty in using a conventional hearing aid and percutaneous BCIs. Patient satisfaction with BCIs differed between BB and Baha.